ClinicalTrials.gg
CompletedNCT02868996Updated Dec 7, 2017

An Open Label, Phase 1b, Ascending Dose Study of DM199

A Phase 1 interventional study of Recombinant human tissue kallikrein in Stroke, sponsored by DiaMedica Therapeutics Inc. Completed at 1 site in Australia. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-07.

Sponsored by DiaMedica Therapeutics Inc · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies in Stroke with a site in Australia — 22 open to participants now, 29 under way, 11 of them phase 3. Stroke · Australia.

Enrollment
95th of 108
36 · median 569
Started
2016
with 4 others
Phase 1
5 of 122
none open now
Registered
69th of 122
by date

Among the 122 studies in Stroke with a site in Australia, this one is the 95th largest by enrollment of the 108 interventional ones that give a count, is one of 5 that started in 2016, is one of 5 in phase 1, and was the 69th registered.

Stroke

8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.

Browse Stroke studies →

Open to participants now

22 of the 122 studies in Stroke with a site in Australia are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,419 Stroke studies recruiting now, 695 (49%) set no upper age limit and 283 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Stroke with a site in Australia, or all of them as a file.
02

Study summary

This is a Phase 1B study to assess the safety, tolerability and pharmacokinetics of DM199 in healthy volunteers. The study will be consist of two parts: Part A will focus on intravenous dosing and Part B will directly compare intravenous dosing with subcutaneous dosing.

03

Conditions studied

  • Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female between 18 and 50 years of age (inclusive);
  2. Healthy with no medical problems;
  3. between 18 to 30 kg/m2 with a weight between 50 to 100 kg (both inclusive);
  4. No history of alcohol or drug abuse (Paracetamol, Barbiturates, Benzodiazepines, Cocaine, Methadone, Amphetamines, Methamphetamines, Opiates, Phencyclidine, Tetrahydrocannabinol (cannabis), Tricyclic Antidepressants). Subjects should be enrolled only after passing the urine drug screen (positive test for paracetamol will be allowed);
  5. Non-smokers or light smokers (Less than 5 cigarettes per day) by history and planned during the study;
  6. No history of significant allergic diathesis such as urticaria, angioedema or anaphylaxis;
  7. Receiving no chronic medications that affect blood pressure control, the bradykinin or angiotensin system including angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB);
  8. Willing and able to sign written, .

Exclusion criteria

Exclusion Criteria:

  1. Any significant past or current cardiac, pulmonary, hepatic, renal or other medical condition which in the opinion of the investigator would make participation of the subject in this study medically unsafe or compromise the accuracy of assessment of safety, pharmacokinetic and pharmacodynamic data of the study;
  2. Subjects who have abnormal safety labs outside the local lab ranges will be excluded at PI's discretion based on his/her assessment of clinical significance (can be repeated once at screening at PI's discretion);
  3. Subjects with past medical history of except basal cell or squamous cell carcinoma of the skin who have had curative surgical treatment and at least 6 months have elapsed since the procedure;
  4. A value outside the specified range of 90 mm Hg - 140 mm Hg for systolic blood pressure and 50 mm Hg - 90 mm Hg for diastolic blood pressure (both inclusive) at screening (can be repeated once at screening as per PI's discretion);
  5. Subjects using angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) to control blood pressure;
  6. History of acute bacterial, viral, or fungal systemic infections in the last 4 weeks prior to screening;
  7. Clinical or laboratory evidence of an active infection at the time of screening;
  8. Known alpha 1-antitrypsin deficiency (α1-antitrypsin deficiency);
  9. Serological evidence of (HIV), surface antigen (HBsAg), or anti- virus (Anti-HCV) at screening;
  10. Vaccination within 3 months of screening for the study or requiring vaccination during the study or within 3 months after completion of the study;
  11. Females who are pregnant or nursing;
  12. Females of (i.e., any woman who is not surgically sterile e.g., hysterectomy, bilateral oophorectomy or >1-year status confirmed by follicle-stimulating hormone (FSH) levels as defined by established lab ranges) and all men who, if participating in heterosexual sexual activity that could lead to pregnancy are unable or unwilling to practice medically effective during the study. They should agree to use two reliable methods of contraception (e.g., double-barrier condom plus diaphragm, condom or diaphragm plus a stable dose of hormonal contraception) throughout the study period and until 3 months after receiving study drug. Women of childbearing potential will require compulsory pregnancy testing. A negative pregnancy test (serum and urine) will be documented during screening and at Day -1 respectively;
  13. Participation in any other drug study within 8 weeks or 5 half-lives of the study drug, whichever is longer;
  14. Unable or unwilling to comply with the protocol requirements for study visits and procedures;
  15. Subjects who do not have good venous access for infusion of study drug or for blood sampling;
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Low dose (Part A)

    Recombinant human tissue kallikrein

    Drug: Recombinant human tissue kallikrein

  • Experimental
    Medium low dose (Part A)

    Recombinant human tissue kallikrein

    Drug: Recombinant human tissue kallikrein

  • Experimental
    Medium high dose (Part A)

    Recombinant human tissue kallikrein

    Drug: Recombinant human tissue kallikrein

  • Experimental
    High dose (Part A)

    Recombinant human tissue kallikrein

    Drug: Recombinant human tissue kallikrein

  • Experimental
    Subcutaneous (Part B)

    Recombinant human tissue kallikrein

    Drug: Recombinant human tissue kallikrein

  • Experimental
    IV (Part B)

    Recombinant human tissue kallikrein

    Drug: Recombinant human tissue kallikrein

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Assessment of safety of intravenous dosing

    Time frame: 30 days

Secondary outcomes

  1. Concentration of DM199 in plasma

    Assess plasma drug levels

    Time frame: 3 days

  2. Concentration of bradykinin in plasma

    Assess drug associated biomarkers (e.g. plasma bradykinin levels)

    Time frame: 3 days

07

Study locations

1 site
  • Linear Clinical Research
    Perth, Western Australia, Australia
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2016, a primary completion of Mar 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2016
First posted
Aug 16, 2016
Start
Sep 2016
Primary completionActual
Mar 2017
CompletionActual
Mar 2017
Last update
Dec 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02868996
Lead sponsor
DiaMedica Therapeutics Inc
Collaborators
Novotech (Australia) Pty Limited
Responsible party
Sponsor
First posted
Aug 16, 2016
Start date
Sep 2016
Primary completion
Mar 2017
Completion
Mar 2017
Last update
Dec 7, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DM199

Start the discussion